期刊文献+

中医护理对康柏西普治疗脉络膜新生血管患者的影响 被引量:1

下载PDF
导出
摘要 脉络膜新生血管是异常新生血管在视网膜下生长,可造成视网膜渗出、水肿,影响患者视力,常继发于年龄相关性黄斑变性、病理性近视等。康柏西普是目前抗血管内皮生长因子常用药物之一,通过抑制血管内皮生长因子和受体的结合,发挥治疗作用[1]。患者在治疗期间心理状况和治疗效果关系很大,应该积极应对患者的不良情绪。目前护理专家在单纯的眼科护理中加入了中医护理的因素,对患者的治疗效果起到了积极的作用。把患者病情进行中医分型,根据结果辨证施护,更具有针对性和个性化。本研究旨在探讨特色的中医护理对脉络膜新生血管患者视力、不良心理和患者满意度的影响。结果显示中医护理可改善患者负面情绪,促进患者视力恢复,提高患者对护理治疗的满意度。
作者 马秀珍
出处 《中国药物与临床》 CAS 2021年第1期170-171,共2页 Chinese Remedies & Clinics
  • 相关文献

参考文献2

二级参考文献22

  • 1Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis [J]. Ophthalmology, 2012, 119(3): 571-580.
  • 2American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern? Guidelines: comprehensive adult medical eye evaluation E EB/OL]. San Francisco: American Academy of Ophthalmology, 2010 [ 2010-09-11 ]. http://one. Aao. Org/ CE/ Practice Guidelines/ PPP. Asox? o: 1.
  • 3Takashi U, Yasuo N, Takuhiro Y, et al. Systemic vascular safety of ranibizumah for age-related macular degeneration: systematic review and meta-analysis of randomized trials [J]. Ophthalmology, 2014, 121(11) :2193-2203.
  • 4Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration [J]. Clin Ophthalmol, 2008, 2(2) :377-388.
  • 5Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12- month randomized phase 2 study: AURORA study [J]. Ophthalmology, 2014, 121(9) :1740-1747.
  • 6Wang Q, Li T,Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J/OL]. PLoS One, 2013, 8(8) : 70544[2013-08-12]. http://dx, plos. org/10. 1371/ journal, pone. 0070544.
  • 7Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration [J]. N Engl J Med, 2006, 355:1419-1431.
  • 8Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study [J]. Ophthalmology, 2009, 116(1) :57-65.
  • 9Singer MA, Awh CC, Sadda S, et al. HORIZON: an openlabel extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration [J]. Ophthalmology, 2012, 119(6) :1175-1183.
  • 10Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)[J]. Ophthalmology, 2013, 120(11) : 2292-2299.

共引文献76

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部